Acute Kidney Injury
Conditions
Keywords
regional citrate anticoagulation, continuous kidney replacement therapy, metabolic complications, electrolyte disorders
Brief summary
This study is a pragmatic, randomized trial comparing two commercially available citrate solutions to determine their impact on metabolic complications in critically ill patients with acute kidney injury receiving continuous kidney replacement therapy with regional citrate anticoagulation.
Detailed description
This study is a pragmatic, randomized trial comparing two commercially available citrate solutions to determine their impact on metabolic complications in critically ill patients with acute kidney injury receiving continuous kidney replacement therapy with regional citrate anticoagulation.
Interventions
DEVICElow concentrated citrate solution (18 mmol/L)
use of a low concentrated citrate solution (18 mmol/L)
DEVICEhigh concentrated citrate solution (136 mmol/L)
high concentrated citrate solution (136 mmol/L)
Sponsors
University Hospital, Antwerp
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Any adult patient admitted to the intensive care unit with acute kidney injury requiring continuous kidney replacement therapy
Exclusion criteria
* expected duration of continuous kidney replacement therapy less than 96 hours * prior continuous kidney replacement therapy before inclusion * a known hypersensitivity to citrate, acute liver failure or liver cirrhosis Child-Pugh C * persistent severe hemodynamic shock with decreased lactate clearance * a high likelihood of dying within the first 24h after initiation of CKRT * preexisting severe electrolyte disorders before CKRT initiation not attributable to Acute kidney injury
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Need for additional electrolyte supplementation | 96 hours | Need for additional electrolyte supplementation : magnesium, phosphate, potassium |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time course of serum electrolyte concentrations | 96 hours | Time course of serum electrolyte concentrations |
| Incidence of electrolyte and acid-base disorders | 96 hours | Incidence of electrolyte and acid-base disorders |
Countries
Belgium
Outcome results
None listed